BBIO vs BBY · rev $221.9M vs P/E 14, rev $41.53B
BridgeBio Pharma Inc (BBIO) versus Best Buy Co. Inc (BBY) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Best Buy Co. Inc (BBY) is a specialty retail company listed on NYSE.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported BBY revenue for 2025-02-01 was $41.53B. Net income was $927.0M. Revenue was down 4.4% from 2024-02-03 to 2025-02-01. BBY currently screens at market cap $15.41B and trailing P/E 13.5.
BBIO currently screens at market cap $13.24B. BBY currently screens at market cap $15.41B and trailing P/E 13.5.
Not investment advice. Open the BBIO and BBY stock pages for the full models.
Not investment advice.